TENS + Physical Therapy: First Real-World Trial

TENS + Physical Therapy: First Real-World Trial

A landmark study published in JAMA Network Open (March 27, 2026) confirms that combining transcutaneous electrical nerve stimulation (TENS) with outpatient physical therapy significantly reduces movement-evoked pain and fatigue in fibromyalgia. New 180-day follow-up data, reported in August 2026, show the benefit holds up over time rather than fading after the initial weeks.

The FM-TIPS Study

The FM-TIPS trial (Fibromyalgia TENS in Physical Therapy) was led by Kathleen Sluka, PT, Ph.D. of the University of Iowa Health Care and is notable for being the first "real-world" trial of TENS for fibromyalgia. Unlike controlled laboratory settings, this study ran across 28 outpatient clinics in six Midwestern health systems, enrolling 384 participants from diverse backgrounds — approximately half from rural areas.

Participants were randomized to receive either physical therapy alone or physical therapy combined with a TENS device. The TENS group used the device for two hours daily, with electrodes placed on the upper and lower back delivering mixed-frequency signals. Scheduling was flexible to accommodate daily life.

What the Day 60 Results Show

By day 60 (the primary endpoint), the combination group showed significant reductions in movement-evoked pain — the specific type of pain that makes daily activity, exercise, and even walking difficult. Resting pain and fatigue also decreased substantially.

• 72% reported meaningful improvement (Patient Global Impression of Change), compared with 51% on physical therapy alone
• 41% achieved a clinically meaningful pain reduction of 30% or more, versus 13% on physical therapy alone (P<.001)
• No serious adverse events were reported

Crucially, the treatment was found to deliver benefits comparable to FDA-approved fibromyalgia medications, without the systemic side effects those drugs carry.

What the Day 180 Follow-Up Adds

Longer-term results, reported by Healio on August 28, 2026, show the effect isn't a short-term novelty:

• 81% of TENS users still found the device helpful at the 6-month mark
• 55% were still using it daily
• Benefits showed a dose-dependent pattern — more consistent daily use correlated with greater relief
• No tolerance or dependency was observed over time

Why This Matters

Dr. Sluka noted: "It is one of the few treatments that specifically targets movement-evoked pain and fatigue, which are major barriers to participation in daily activities." For fibromyalgia patients, the ability to move with less pain is often the difference between isolation and engagement.

TENS devices are widely available and relatively affordable, making this a potentially accessible option for patients who cannot tolerate or access pharmacological treatments.